Chase’s lead candidate is CPC-201, an oral combination of donepezil, an acetylcholinesterase inhibitor (AChEI), and a peripherally acting cholinergic blocker for the treatment of Alzheimer’s disease. Donepezil is the current standard-of-care for symptomatic treatment of Alzheimer’s disease. The cognitive decline associated with Alzheimer’s disease is related to an acetylcholine deficit in the cholinergic neurotransmitter system. Donepezil binds to and inactivates cholinesterase enzymes that breakdown acetylcholine, thereby increasing acetylcholine concentrations and duration at cholinergic synapses, enhancing communication in the brain and improving cognition.
While donepezil is the standard of care for Alzheimer’s disease patients, it is only modestly effective in improving cognition because significant gastrointestinal side effects – e.g., retching, diarrhea, nausea, and vomiting -- limit the ability to tolerably dose donepezil to optimally efficacious levels.
Chase believes pairing donepezil with a peripherally acting cholinergic blocker will reduce tolerability-limiting side effects, allowing significantly higher doses of donepezil and thus significantly improving acetylcholine concentrations and cognitive and functional benefits.
Chase has successfully completed multiple Phase 1 studies of CPC-201. Its Phase 2 trial of CPC-201 in patients with moderate Alzheimer's disease is expected to be completed in the first half of 2016.
Chase intends to commence its Phase 3 registration program for CPC-201 in the second half of 2016.